Form 4: Design Therapeutics CMO Granted 400,000 Stock Options in Executive Compensation Move

Design Therapeutics' Chief Medical Officer, Chris Storgard, was granted 400,000 stock options with an exercise price of $4.71, vesting over a four-year period.

Summary

• Chris Storgard, the Chief Medical Officer of Design Therapeutics, Inc. (DSGN), acquired 400,000 derivative securities in the form of stock options.
• The stock options have an exercise price of $4.71 per share.
• The transaction date for this grant was May 1, 2025.
• The options will vest according to a schedule: 25% of the shares will vest on April 16, 2026, with the remaining balance vesting in equal monthly installments over the subsequent 36 months.
• The expiration date for these stock options is April 30, 2035.
• Following this transaction, Chris Storgard beneficially owns 400,000 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns management's interests with shareholder value, indicating confidence in future performance and a commitment to executive retention. This is a routine compensation event.

Positives

• The grant of 400,000 stock options to the Chief Medical Officer aligns management's financial interests with long-term shareholder value creation.
• The multi-year vesting schedule (over four years) promotes executive retention and commitment to the company's sustained performance.

Future Outlook

The vesting schedule for the stock options, extending over four years, indicates a long-term commitment from the Chief Medical Officer to the company's future performance and strategic objectives, suggesting a focus on sustained growth.

Management Comments

• The grant of stock options to the Chief Medical Officer reflects the company's strategy for executive compensation and retention, aiming to incentivize long-term value creation.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries to incentivize and retain key executives, aligning their financial interests with the long-term success and share price performance of the company.

Comparison to Industry Standards

• The use of stock options as a component of executive compensation is a standard practice across the biotechnology and pharmaceutical sectors, comparable to compensation structures observed in companies like Moderna, Pfizer, or Gilead Sciences, which often utilize equity incentives to attract and retain top talent.

Related Party Transactions

• The grant of stock options to Chris Storgard, the Chief Medical Officer, constitutes a related party transaction as it involves compensation provided by the company to a key executive.

Stakeholder Impact

• Shareholders may benefit from increased alignment of management's interests with long-term company performance due to the equity incentive, potentially leading to improved stock performance.
• Employees, particularly other executives, may view this as a positive signal regarding the company's commitment to competitive compensation practices.

Next Steps

• The vesting of the granted stock options will occur in stages, with the first 25% vesting on April 16, 2026, and the remainder vesting monthly over the subsequent 36 months.

Key Dates

Keywords

Design Therapeutics, DSGN, Stock Options, Executive Compensation, Insider Transaction, Form 4, Chief Medical Officer, Chris Storgard, Equity Incentive